Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2019 · 10-Q
Revenue$5.00M$5.00M−7.6% vs Q3 2018 Net Income-$1.57M-$1.57MN/M vs Q3 2018 EPS Diluted-$0.11-$0.11N/M vs Q3 2018 Gross Profit$3,021,624−4.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$969,059N/M Free Cash Flowderived-$982,777N/M Margins · derivedGross margin60.4%+2.3 pt vs Q3 2018
Operating margin-39.7%−43.8 pt vs Q3 2018
Net margin-31.4%−35.9 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 5, 2019 · 36 d after period end